BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32873407)

  • 1. Cancer Nanomedicines in an Evolving Oncology Landscape.
    Guo P; Huang J; Moses MA
    Trends Pharmacol Sci; 2020 Oct; 41(10):730-742. PubMed ID: 32873407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors.
    Han X; Xu Y; Geranpayehvaghei M; Anderson GJ; Li Y; Nie G
    Biomaterials; 2020 Feb; 232():119745. PubMed ID: 31918228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging Bio-Nano Science and Cancer Nanomedicine.
    Björnmalm M; Thurecht KJ; Michael M; Scott AM; Caruso F
    ACS Nano; 2017 Oct; 11(10):9594-9613. PubMed ID: 28926225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
    Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
    Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
    Fletcher NL; Kempe K; Thurecht KJ
    Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
    Zhang Y; Li J; Pu K
    Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for cancer therapy: current status, challenges and future prospects.
    Bor G; Mat Azmi ID; Yaghmur A
    Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carrier-Free Nanomedicine for Cancer Immunotherapy.
    Fu Y; Bian X; Li P; Huang Y; Li C
    J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional Cargo-Free Nanomedicine for Cancer Therapy.
    Wang Y; Yang P; Zhao X; Gao D; Sun N; Tian Z; Ma T; Yang Z
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Incorporated Nanomedicines for Cancer Therapy.
    Wu SY; Wu FG; Chen X
    Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer nanomedicine meets immunotherapy: opportunities and challenges.
    Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y
    Acta Pharmacol Sin; 2020 Jul; 41(7):954-958. PubMed ID: 32555445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing cancer immunotherapy with nanomedicine.
    Irvine DJ; Dane EL
    Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances and clinical translation of liposomal delivery systems in cancer therapy.
    Chen J; Hu S; Sun M; Shi J; Zhang H; Yu H; Yang Z
    Eur J Pharm Sci; 2024 Feb; 193():106688. PubMed ID: 38171420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.